Pharmaxis Announces Encouraging Results from Phase 1c Study of Topical Pan LOX Inhibitor in Established Skin Scars

23rd May 23

Release Date: 23/05/2023 4:34pm

  • Well tolerated with good safety profile
  • Marked change in scar composition with 30% reduction in collagen content
  • First ever proof that LOX inhibition reduces skin collagen underpins expansion of Pharmaxis and Professor Fiona Wood collaboration into new skin fibrosis indications
  • No overall improvements in scar appearance seen at 3 months points to need for longer study in established scars

Read full media release - pdf

Categories: News and Media